Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders





Income Statement
Balance Sheet
Cash Flow Statement

Common Size IS
Op Efficiency
Credit Analysis

Lyra Therapeutics, Inc. (LYRA)

Income Statement

Standardized | As Reported Annual | Quarterly | TTM
 
In millions, except per share itemsDec-31-21Dec-31-20Dec-31-19Dec-31-18
   10-K10-K10-KS-1/A
Revenues  0.30.00.05.0
            Revenue growth    -100.0% 
Cost of goods sold  0.00.00.08.7
Gross profit  0.30.00.0-3.7
            Gross margin  100.0%  -75.0%
Selling, general and administrative   [+]14.29.74.53.5
Research and development  29.712.512.0 
EBITDA   [+]-42.6-22.1-16.5-7.2
            EBITDA margin  -14952.3%  -144.3%
Depreciation and amortization  1.00.10.00.1
EBIT   [+]-43.6-22.2-16.5-7.3
            EBIT margin  -15303.5%  -145.9%
Interest income  0.10.10.20.0
Other income (expense), net     1.2
Pre-tax income  -43.5-22.1-16.3-6.0
Income taxes  0.00.00.00.0
            Tax rate  0.0%0.0%0.0%0.0%
Net income  -43.5-22.1-16.3-6.0
            Net margin  -15267.7%  -121.2%
   
Basic EPS   [+]($3.35)($2.58)($80.69)($36.30)
Diluted EPS   [+]($3.35)($2.58)($80.69)($36.30)
   
Shares outstanding (basic)   [+]13.08.60.20.2
Shares outstanding (diluted)   [+]13.08.60.20.2
   
EBIT is a non-GAAP figure that excludes all non-recurring expenses: restructuring costs, asset impairments, IPR&D writeoffs, and other unusual charges.  

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy